Current progress on aptamer-targeted oligonucleotide therapeutics

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature411(6836),494–498 (2001).
  Medline CASGoogle Scholar
• 2  Kole R, Krainer AR, Altman S. RNA therapeutics. beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug. Discov.11(2),125–140 (2012).
  Medline CASGoogle Scholar
• 3  Juliano RL, Ming X, Nakagawa O. Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug. Chem.23(2),147–157 (2012).
  Medline CASGoogle Scholar
• 4  Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res.36(12),4158–4171 (2008).
  Medline CASGoogle Scholar
• 5  Coelho T, Adams D, Silva A et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med.369(9),819–829 (2013).
  Medline CASGoogle Scholar
• 6  Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med.368(18),1685–1694 (2013).
  Medline CASGoogle Scholar
• 7  Barros SA, Gollob JA. Safety profile of RNAi nanomedicines. Adv. Drug Deliv. Rev.64(15),1730–1737 (2012).
  Medline CASGoogle Scholar
• 8  Sehgal A, Vaishnaw A, Fitzgerald K. Liver as a target for oligonucleotide therapeutics. J. Hepatol. doi:10.1016/j.jhep.2013.05.045 (2013) (Epub ahead of print).
  MedlineGoogle Scholar
• 9  Gavrilov K, Saltzman WM. Therapeutic siRNA. principles, challenges, and strategies. Yale J. Biol. Med.85(2),187–200 (2012).
  Medline CASGoogle Scholar
• 10  Ramsey JM, Hibbitts A, Barlow J, Kelly C, Sivadas N, Cryan SA. ‘Smart’ non-viral delivery systems for targeted delivery of RNAi to the lungs. Ther. Deliv.4(1),59–76 (2013).
  CASGoogle Scholar
• 11  Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides21(1),1–10 (2011).
  MedlineGoogle Scholar
• 12  Zhou J, Bobbin ML, Burnett JC, Rossi JJ. Current progress of RNA aptamer-based therapeutics. Front. Genet.3,234 (2012).
  Medline CASGoogle Scholar
• 13  Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence1(1),4 (2010).
  MedlineGoogle Scholar
• 14  Thiel KW, Giangrande PH. Intracellular delivery of RNA-based therapeutics using aptamers. Ther. Deliv.1(6),849–861 (2010).
  CASGoogle Scholar
• 15  Robertson DL, Joyce GF. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature344(6265),467–468 (1990).
  Medline CASGoogle Scholar
• 16  Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment. RNA ligands to bacteriophage T4 DNA polymerase. Science249(4968),505–510 (1990).▪▪ First study to coin the term systematic evolution of ligands by exponential.
  Medline CASGoogle Scholar
• 17  Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature346(6287),818–822 (1990).▪▪ This study and the one by Tuerk and Gold (1990) provided the first demonstration of an in vitro selection methodology (systematic evolution of ligands by exponential) for identifying RNA aptamers with affinity and specificity for a given target.
  Medline CASGoogle Scholar
• 18  Stoltenburg R, Reinemann C, Strehlitz B. SELEX – a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng.24(4),381–403 (2007).
  Medline CASGoogle Scholar
• 19  Mosing RK, Bowser MT. Microfluidic selection and applications of aptamers. J. Sep. Sci.30(10),1420–1426 (2007).
  Medline CASGoogle Scholar
• 20  Thiel KW, Hernandez LI, Dassie JP et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res.40(13),6319–6337 (2012).
  Medline CASGoogle Scholar
• 21  Thiel WH, Bair T, Peek AS et al. Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS ONE7(9),e43836 (2012).
  Medline CASGoogle Scholar
• 22  Cerchia L, Duconge F, Pestourie C et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol.3(4),e123 (2005).
  MedlineGoogle Scholar
• 23  Blank M, Weinschenk T, Priemer M, Schluesener H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen. J. Biol. Chem.276(19),16464–16468 (2001).
  Medline CASGoogle Scholar
• 24  Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX. Systematic evolution of ligands by exponential enrichment. Proc. Natl Acad. Sci. USA100(26),15416–15421 (2003).
  Medline CASGoogle Scholar
• 25  Shamah SM, Healy JM, Cload ST. Complex Target SELEX. Acc. Chem Res.41(1),130–138 (2008).
  Medline CASGoogle Scholar
• 26  Sefah K, Tang ZW, Shangguan DH et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia23(2),235–244 (2009).
  Medline CASGoogle Scholar
• 27  Shangguan D, Meng L, Cao ZC et al. Identification of liver cancer-specific aptamers using whole live cells. Anal. Chem.80(3),721–728 (2008).
  Medline CASGoogle Scholar
• 28  Guo K-T, Paul A, Schichor C, Ziemer G, Wendel HP. CELL-SELEX. Novel perspectives of aptamer-based therapeutics. Int. J. Mol. Sci.9(4),668–678 (2008).
  Medline CASGoogle Scholar
• 29  Morris KN, Jensen KB, Julin CM, Weil M, Gold L. High affinity ligands from in vitro selection: complex targets. Proc. Natl Acad. Sci. USA95(6),2902–2907 (1998).
  Medline CASGoogle Scholar
• 30  Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat. Rev. Drug. Discov.9(7),537–550 (2010).
  Medline CASGoogle Scholar
• 31  Sundaram P, Kurniawan H, Byrne ME, Wower J. Therapeutic RNA aptamers in clinical trials. Eur. J. Pharm. Sci.48(1–2),259–271 (2013).
  Medline CASGoogle Scholar
• 32  Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell63(3),601–608 (1990).
  Medline CASGoogle Scholar
• 33  Lee JH, Yigit MV, Mazumdar D, Lu Y. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv. Drug Deliv. Rev.62(6),592–605 (2010).
  Medline CASGoogle Scholar
• 34  Dassie JP, Liu XY, Thomas GS et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol.27(9),839–849 (2009).▪▪ Optimization of the first-generation prostate-specific membrane antigen aptamer-siRNA chimera achieved systemic delivery in an in vivo model of prostate cancer.
  Medline CASGoogle Scholar
• 35  Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature465(7295),227–230 (2010).▪▪ This groundbreaking tumor immunotherapy study used aptamers to deliver siRNAs against components of the nonsense-mediated mRNA decay pathway, which generated novel antigens on the surface of PSMA+ and tumor cells and resulted in an immune response to the tumor.
  Medline CASGoogle Scholar
• 36  Wheeler LA, Trifonova R, Vrbanac V et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Invest.121(6),2401–2412 (2011).
  Medline CASGoogle Scholar
• 37  Wheeler LA, Vrbanac V, Trifonova R et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol. Ther.21(7),1378–1389 (2013).
  Medline CASGoogle Scholar
• 38  Zhou J, Neff CP, Swiderski P et al. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol. Ther.21(1),192–200 (2013).
  Medline CASGoogle Scholar
• 39  Neff CP, Zhou J, Remling L et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci. Transl. Med.3(66),66ra6 (2011).
  MedlineGoogle Scholar
• 40  Ni X, Zhang Y, Ribas J et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J. Clin. Invest.121(6),2383–2390 (2011).
  Medline CASGoogle Scholar
• 41  Burnett JC, Rossi JJ. RNA-based therapeutics. current progress and future prospects. Chem. Biol.19(1),60–71 (2012).
  Medline CASGoogle Scholar
• 42  Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides18(4),305–319 (2008).
  Medline CASGoogle Scholar
• 43  Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol. Ther.20(3),483–512 (2012).
  Medline CASGoogle Scholar
• 44  Ge Q, Dallas A, Ilves H, Shorenstein J, Behlke MA, Johnston BH. Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA16(1),118–130 (2010).
  Medline CASGoogle Scholar
• 45  Kolkenbeck K, Zundel G. The significance of the 2´ OH group and the influence of cations on the secondary structure of the RNA backbone. Biophys. Struct. Mech.1(3),203–219 (1975).
  Medline CASGoogle Scholar
• 46  Campbell MA, Wengel J. Locked vs. unlocked nucleic acids (LNA vs. UNA). contrasting structures work towards common therapeutic goals. Chem. Soc. Rev.40(12),5680–5689 (2011).
  Medline CASGoogle Scholar
• 47  Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther.292(2),468–479 (2000).
  Medline CASGoogle Scholar
• 48  Peacock H, Fucini RV, Jayalath P et al. Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA. J. Am. Chem. Soc.133(24),9200–9203 (2011).
  Medline CASGoogle Scholar
• 49  Keefe AD, Cload ST. SELEX with modified nucleotides. Curr. Opin. Chem. Biol.12(4),448–456 (2008).
  Medline CASGoogle Scholar
• 50  Reese CB. Oligo- and poly-nucleotides. 50 years of chemical synthesis. Org. Biomol. Chem.3(21),3851–3868 (2005).
  Medline CASGoogle Scholar
• 51  Rockey WM, Hernandez FJ, Huang SY et al. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther.21(5),299–314 (2011).
  Medline CASGoogle Scholar
• 52  Thiel KW, Giangrande PH. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides19(3),209–222 (2009).
  Medline CASGoogle Scholar
• 53  Boomer RM, Lewis SD, Healy JM, Kurz M, Wilson C, Mccauley TG. Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides15(3),183–195 (2005).
  Medline CASGoogle Scholar
• 54  Healy JM, Lewis SD, Kurz M et al. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res.21(12),2234–2246 (2004).
  Medline CASGoogle Scholar
• 55  Bozza M, Sheardy RD, Dilone E, Scypinski S, Galazka M. Characterization of the secondary structure and stability of an RNA aptamer that binds vascular endothelial growth factor. Biochemistry45(24),7639–7643 (2006).
  Medline CASGoogle Scholar
• 56  Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J. Control. Release151(3),220–228 (2011).
  Medline CASGoogle Scholar
• 57  Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther.16(8),1481–1489 (2008).▪▪ An inhibitory aptamer was combined with a silencing siRNA to deliver a two-hit punch to HIV-infected T cells.
  Medline CASGoogle Scholar
• 58  Mcnamara JO, 2nd, Andrechek ER, Wang Y et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol.24(8),1005–1015 (2006).▪▪ Established aptamer-siRNA chimeras as a platform technology to specifically deliver siRNAs against prosurvival genes to prostate specific membrane antigen+ human prostate cancer tumors.
  Medline CASGoogle Scholar
• 59  Zhou J, Tiemann K, Chomchan P et al. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res.41(7),4266–4283 (2013).
  Medline CASGoogle Scholar
• 60  Hussain AF, Tur MK, Barth S. An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin. Nucleic Acid Ther.23(3),203–212 (2013).
  Medline CASGoogle Scholar
• 61  Dai F, Zhang Y, Zhu X, Shan N, Chen Y. Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target. Oncol.7(4),217–225 (2012).
  MedlineGoogle Scholar
• 62  Thiel KW, Hernandez LI, Dassie JP et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acid Res.40(13),6319–6337 (2012).
  Medline CASGoogle Scholar
• 63  Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res.62(14),4029–4033 (2002).▪ Prostate-specific membrane antigen A9 and A10 aptamers characterized in this study were the initial aptamers used, in subsequent studies, to deliver siRNAs to target cells.
  Medline CASGoogle Scholar
• 64  Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets8(7),554–565 (2008).
  Medline CASGoogle Scholar
• 65  Mi J, Zhang X, Giangrande PH et al. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem. Biophys. Res. Commun.338(2),956–963 (2005).
  Medline CASGoogle Scholar
• 66  Chattopadhyay N, Chatterjee A. Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues. J. Exp. Clin. Cancer Res.20(2),269–275 (2001).
  Medline CASGoogle Scholar
• 67  Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br. J. Cancer82(12),1967–1973 (2000).
  Medline CASGoogle Scholar
• 68  Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr. Relat. Cancer15(3),657–664 (2008).
  Medline CASGoogle Scholar
• 69  Novak AJ, Grote DM, Stenson M et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma. Correlation with disease activity and patient outcome. Blood104(8),2247–2253 (2004).
  Medline CASGoogle Scholar
• 70  He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet.5(7),522–531 (2004).
  Medline CASGoogle Scholar
• 71  Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer. rationale, strategies and challenges. Nat. Rev. Drug. Discov.9(10),775–789 (2010).
  Medline CASGoogle Scholar
• 72  Cerchia L, Esposito CL, Camorani S et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol. Ther.20(12),2291–2303 (2012).
  Medline CASGoogle Scholar
• 73  Karam R, Wengrod J, Gardner LB, Wilkinson MF. Regulation of nonsense-mediated mRNA decay. implications for physiology and disease. Biochim. Biophys. Acta1829(6–7),624–633 (2013).
  Medline CASGoogle Scholar
• 74  Nemunaitis J. Vaccines in cancer. GVAX, a GM-CSF gene vaccine. Expert Rev. Vaccines4(3),259–274 (2005).
  Medline CASGoogle Scholar
• 75  Wang CW, Chung WH, Cheng YF et al. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. J. Allergy Clin. Immunol.132(3),713–722 (2013).
  Medline CASGoogle Scholar
• 76  Khati M, Schuman M, Ibrahim J, Sattentau Q, Gordon S, James W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2´F-RNA aptamers. J. Virol.77(23),12692–12698 (2003).
  Medline CASGoogle Scholar
• 77  Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol.23(2),222–226 (2005).
  Medline CASGoogle Scholar
• 78  Zhou J, Swiderski P, Li H et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res.37(9),3094–3109 (2009).▪ New anti-gp120 inhibitory aptamers were identified and a unique ‘sticky bridge’ strategy was introduced to non-covalently conjugate siRNAs to the gp120 aptamer.
  Medline CASGoogle Scholar
• 79  Davis KA, Lin Y, Abrams B, Jayasena SD. Staining of cell surface human CD4 with 2´-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucleic Acid Res.26(17),3915–3924 (1998).
  Medline CASGoogle Scholar
• 80  Kortylewski M, Swiderski P, Herrmann A et al.In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol.27(10),925–932 (2009).
  Medline CASGoogle Scholar
• 81  Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl Acad. Sci. USA93(7),2879–2883 (1996).
  Medline CASGoogle Scholar
• 82  Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374(6522),546–549 (1995).
  Medline CASGoogle Scholar
• 83  Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene27(2),161–167 (2008).
  Medline CASGoogle Scholar
• 84  Barchet W, Wimmenauer V, Schlee M, Hartmann G. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin. Immunol.20(4),389–395 (2008).
  Medline CASGoogle Scholar
• 85  Verthelyi D, Wang VW, Lifson JD, Klinman DM. CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS18(7),1003–1008 (2004).
  Medline CASGoogle Scholar
• 86  Girvan AC, Teng Y, Casson LK et al. AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin. Mol. Cancer Ther.5(7),1790–1799 (2006).
  Medline CASGoogle Scholar
• 87  Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol. Cancer Ther.5(12),2957–2962 (2006).
  Medline CASGoogle Scholar
• 88  Kotula JW, Pratico ED, Ming X, Nakagawa O, Juliano RL, Sullenger BA. Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther.22(3),187–195 (2012).
  Medline CASGoogle Scholar
• 89  Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J, Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS ONE5(12),e15787 (2010).
  Medline CASGoogle Scholar
• 90  Kang SH, Cho MJ, Kole R. Up-regulation of luciferase gene expression with antisense oligonucleotides. implications and applications in functional assay development. Biochemistry37(18),6235–6239 (1998).
  Medline CASGoogle Scholar
• 91  Kole R, Vacek M, Williams T. Modification of alternative splicing by antisense therapeutics. Oligonucleotides14(1),65–74 (2004).
  Medline CASGoogle Scholar
• 92  Kole R, Williams T, Cohen L. RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim. Pol.51(2),373–378 (2004).
  Medline CASGoogle Scholar
• 93  Ferreira CS, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker. design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol.27(6),289–301 (2006).
  Medline CASGoogle Scholar
• 94  Constantinou PE, Danysh BP, Dharmaraj N, Carson DD. Transmembrane mucins as novel therapeutic targets. Expert Rev. Endocrinol. Metab.6(6),835–848 (2011).
  Medline CASGoogle Scholar
• 95  Zhu Q, Shibata T, Kabashima T, Kai M. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur. J. Med. Chem.56,396–399 (2012).
  Medline CASGoogle Scholar
• 96  Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev. Clin Immunol.7(6),803–813; quiz 814–815 (2011).
  MedlineGoogle Scholar
• 97  Shlomchik WD. Graft-versus-host disease. Nat. Rev. Immunol.7(5),340–352 (2007).
  Medline CASGoogle Scholar
• 98  Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med.14(12),1343–1350 (2008).
  Medline CASGoogle Scholar
• 99  Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons. Curr. Med. Chem.18(27),4206–4214 (2011).
  Medline CASGoogle Scholar
• 100  Shi B, Abrams M. Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery. J. Histochem. Cytochem.61(6),407–420 (2013).
  Medline CASGoogle Scholar
• 101  Musacchio T, Torchilin VP. siRNA delivery: from basics to therapeutic applications. Front. Biosci.18,58–79 (2013).
  CASGoogle Scholar
• 102  Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials33(29),7138–7150 (2012).
  Medline CASGoogle Scholar
• 103  Ye X, Hemida M, Zhang HM, Hanson P, Ye Q, Yang D. Current advances in Phi29 pRNA biology and its application in drug delivery. Wiley Interdiscip. Rev. RNA3(4),469–481 (2012).
  Medline CASGoogle Scholar
• 104  Nimesh S. Recent patents in siRNA delivery employing nanoparticles as delivery vectors. Recent Pat. DNA Gene Seq.6(2),91–97 (2012).
  Medline CASGoogle Scholar
• 105  Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs24(3),195–205 (2010).
  Medline CASGoogle Scholar
• 106  Leucuta SE. Systemic and biophase bioavailability and pharmacokinetics of nanoparticulate drug delivery systems. Curr. Drug Deliv.10(2),208–240 (2013).
  Medline CASGoogle Scholar
• 107  Marcus ME, Leonard JN. FedExosomes: Engineering therapeutic biological nanoparticles that truly deliver. Pharmaceuticals (Basel)6(5),659–680 (2013).
  Medline CASGoogle Scholar
• 108  Kim E, Jung Y, Choi H et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and DOXorubicin using an aptamer-conjugated polyplex. Biomaterials31(16),4592–4599 (2010).
  Medline CASGoogle Scholar
• 109  Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res.64(21),7668–7672 (2004).
  Medline CASGoogle Scholar
• 110  Zhao N, Bagaria HG, Wong MS, Zu Y. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J. Nanobiotechnology9,2 (2011).
  Medline CASGoogle Scholar
• 111  Wu X, Ding B, Gao J et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int. J. Nanomedicine6,1747–1756 (2011).
  Medline CASGoogle Scholar
• 112  Wilner SE, Wengerter B, Maier K et al. An RNA alternative to human transferrin. a new tool for targeting human cells. Mol. Ther. Nucleic Acids1,e21 (2012).
  MedlineGoogle Scholar
• 113  Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov.8(2),129–138 (2009).
  Medline CASGoogle Scholar
• 114  Bagalkot V, Gao X. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano5(10),8131–8139 (2011).
  Medline CASGoogle Scholar
• 115  Kim JK, Choi KJ, Lee M, Jo MH, Kim S. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials33(1),207–217 (2012).
  Medline CASGoogle Scholar
• 116  Guo S, Tschammer N, Mohammed S, Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum. Gene. Ther.16(9),1097–1109 (2005).
  Medline CASGoogle Scholar
• 117  Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. J. Immunol.160(11),5209–5212 (1998).
  Medline CASGoogle Scholar
• 118  Khaled A, Guo S, Li F, Guo P. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett.5(9),1797–1808 (2005).
  Medline CASGoogle Scholar
• 119  Zhou J, Shu Y, Guo P, Smith DD, Rossi JJ. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods54(2),284–294 (2011).
  Medline CASGoogle Scholar
• 120  Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev.59(2–3),134–140 (2007).
  Medline CASGoogle Scholar
• 121  Huang YZ, Hernandez FJ, Gu B et al. RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol Pharmacol82(4),623–635 (2012).
  Medline CASGoogle Scholar
• 122  Zhang S, Zhao Y, Zhi D. Non-viral vectors for the mediation of RNAi. Bioorg. Chem.40(1),10–18 (2012).
  MedlineGoogle Scholar
• 123  Meade BR, Dowdy SF. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv. Drug Deliv. Rev.60(4–5),530–536 (2008).
  Medline CASGoogle Scholar
• 124  Tamura A, Nagasaki Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine (Lond.)5(7),1089–1102 (2010).
  Medline CASGoogle Scholar
• 125  Gilleron J, Querbes W, Zeigerer A et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol.31(7),638–646 (2013).
  Medline CASGoogle Scholar
• 126  Sahay G, Querbes W, Alabi C et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol.31(7),653–658 (2013).
  Medline CASGoogle Scholar
• 127  Nechaev S, Gao C, Moreira D et al. Intracellular processing of immunostimulatory CpG-siRNA. Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J. Control. Release170(3),307–315 (2013).
  Medline CASGoogle Scholar
• 128  Shu D, Shu Y, Haque F, Abdelmawla S, Guo P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat. Nanotechnol.6(10),658–667 (2011).
  Medline CASGoogle Scholar
• 201  Ellington, A. The Ellington Lab Aptamer Database. http://aptamer.icmb.utexas.edu
  Google Scholar